Hotspot Therapeutics Inc. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.

Mironid Ltd. has synthesized phosphodiesterase PDE4 activators reported to be useful for the treatment cancer, hyperparathyroidism, autosomal dominant polycystic kidney disease and autosomal recessive polycystic kidney disease.

Astrazeneca AB has disclosed myeloperoxidase inhibitors reported to be useful for the treatment of cancer, cardiovascular, inflammatory, renal, neurological and respiratory disorders and liver diseases.

Insilico Medicine Inc. has patented new cyclin-dependent kinase 12 (CDK12)/cyclin K and/or CDK13 inhibitors reported to be useful for the treatment of cancer, particularly triple-negative breast cancer.

Work at Bellbrook Labs LLC has led to the identification of cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoimmune diseases.

Ajax Therapeutics Inc. has synthesized heterocyclic amide and urea compounds acting as tyrosine-protein kinase JAK2 inhibitors and thus reported to be useful for the treatment of cancer and myelofibrosis.

A Beijing Danatlas Pharmaceutical Technology Co. Ltd. patent describes tricyclic heterocyclic derivatives acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.

Korea Institute of Radiological and Medical Sciences, Nextgen Bioscience Co. Ltd. and Yonsei University have jointly prepared purine derivative compounds acting as adenosine A3 receptor agonists reported to be useful for the treatment of pulmonary fibrosis.

Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.